- The share
- Press releases
- Financial calendar
- Financial reports
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- CODE OF CONDUCT
- Thank you
First XPS™ sold to Australia and to the Netherlands
Delivery and installation of the Australian XPS™ occurred in March 2017. Delivery of the XPS™ to the Netherlands was made in March 2017 and the installation is estimated to take place in May 2017. Alfred Health in Melbourne is a world leading clinic in the evaluation of DCD lungs (DCD = Donation after Circulatory Death) and has long experience of evaluating lungs using STEEN Solution™. By using XPS™ this process can now become more standardized and the evaluation of lungs can be simplified.
According to the Company’s business model, the pricing strategy for capital goods, that is the EVLP machines LS™ and XPS™, is so designed that sales of capital goods do not have a significant financial impact on the Company. According to the Company’s pricing strategy, future sales of STEEN Solution™ for use in the EVLP machines and accompanying single-use items are of financial significance for the Company.
“We are very pleased and proud that EVLP with XPS™ and STEEN Solution™ will be used to evaluate lungs for transplantation in Australia and the Netherlands. The clinic in Melbourne is a world leader in the evaluation of DCD lungs, an area where the Company sees great potential for growth in the future. The Company continues to see great interest from clinics worldwide in installing EVLP machines to facilitate the evaluation of lungs with a view to using more donated lungs,” says Magnus Nilsson, CEO of XVIVO Perfusion.
April 12, 2017
Magnus Nilsson, CEO
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101, firstname.lastname@example.org
Magnus Nilsson, CEO, +46 31 788 2150, email@example.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 am CET on April 12, 2017.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.